Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lumara Health Inc.

http://www.lumarahealth.com/

Latest From Lumara Health Inc.

Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’

Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Sales & Earnings Commercial

Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’

Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Commercial Biosimilars

Organon Tempers Expectations Ahead Of Adalimumab Second Wave

Ahead of joining a second wave of Humira biosimilars hitting the US market in just a couple of months, Organon has projected a “modest ramp” in initial sales for its Hadlima version in 2023.

Biosimilars United States

Ninth Canadian Jurisdiction Implements Biosimilar Switching Policy

Newfoundland and Labrador has become the ninth jurisdiction in Canada to implement a biosimilar switching policy for patients enrolled on its public health program.

Biosimilars Policy
See All

Company Information

  • Other Names / Subsidiaries
    • Ethex Corporation
    • K-V Pharmaceutical Company (KV Pharmaceutical)
    • Ther-Rx Corporation
UsernamePublicRestriction

Register